Grepafloxacin
| Code | Size | Price |
|---|
| TAR-T38586-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Grepafloxacin (OPC-17116) is an oral actively fluoroquinolone antibiotic with potent activity against community-acquired respiratory pathogens including Streptococcus pneumonia . Grepafloxacin has high tissue penetration and a promising pharmacodynamic profile.
CAS:
119914-60-2
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0
References
Cynamon MH, et al. The activity of grepafloxacin in two murine models of Mycobacterium avium infection. J Infect Chemother. 2004;10(3):185-188.
Efthymiopoulos C. Pharmacokinetics of grepafloxacin. J Antimicrob Chemother. 1997;40 Suppl A:35-43.
Owen K. Comparative grepafloxacin phototoxicity in mouse skin. J Antimicrob Chemother. 1998;42(2):261-264.
Miyamoto H, et al. Synthesis and biological properties of substituted 1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acids. Bioorg Med Chem. 1995;3(12):1699-1706.